<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230529058336N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-12</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Efficacy Of Botulinum Toxin In The Treatment Of Acne</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of Efficacy of Botulinum Toxin In The Treatment Of Acne Vulgaris: A Double-Blind Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-25</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/70441</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly assigned to the group of botox injection on one side of the face and normal saline injection on the opposite side of the face through a double-blind block randomization method. So that each person was considered as a block. Double blocks are made in such a way that AB combination is injected into the right side of the person's face with Botox and normal saline is injected into the left side of the face. To prepare a random list from the table of random numbers to this
It is used that a random number is selected at each step. If the selected number is between 0 and 4, AB combination is considered and if the selected number is 5 to 9, BA combination is considered.Therefore, we repeat this process many times until qualified patients enter the study. According to the output related to Random Allocation Software which is reported as below, the meaning of code 0001:AB
That is, botox is injected into the right side of the first person's face and normal saline is injected into the left side of the first person's face. In addition, code 0002:BA means normal saline will be injected on the right side of the second person's face and Botox will be injected on the left side of the second person's face.

0001: BA 0002: AB
0003: AB 0004: BA
0005: AB 0006: BA
0007: AB 0008: BA
0009: AB 0010: BA
0011: AB 0012: BA
0013: AB 0014: BA
0015: BA 0016: AB
0017: BA 0018: AB
0019: BA 0020: AB
0021: AB 0022: BA
0023: BA 0024: AB
0025: AB 0026: BA
0027: BA 0028: AB
0029: AB 0030: BA, Blinding description: The patient does not know on which side of the face we want to inject Botox or normal saline. Coding is done by one of the colleagues of the project, and the evaluator and the patient are blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Acne vulgaris.</hc_freetext>
      <i_freetext>Intervention group: patients with moderate to severe acne based on the GAGS criteria, which are examined in 6 areas in this system: forehead, right cheek, left cheek, nose, chin and upper body. First, each lesion is given a grade based on its severity: no lesion = 0, comedone = 1, papule = 2, pustule = 3, and nodule = 4. The final score for each location (Local Score) is calculated as follows.Factor × grade, in the end, the global score will be the sum of the local scores. A score of 1 to 18 is mild acne, 19 to 30 is moderate acne, 31 to 38 is severe acne, and more than 39 is very severe acne.Patients' faces are divided into right and left face groups by double-blind randomization method. On the control side, 20 points are selected in one half of the face and a volume of one cc or precisely 0.2 cc of placebo is injected in each point, which is the same as normal saline (12 cheek points, 6 forehead areas and two chin areas are selected) ) and 20 points are selected on their intervention side (the number of areas and their locations are the same as the intervention side) and 20 units of botulinum toxin (Dystone company brand) and 0.2 cc are injected in each point. The injection is done only once. Both sides of the patient's face will be treated with topical clindamycin 2%, which is manufactured by Razi Hospital Pharmacy.Patients are evaluated by the evaluator at the beginning of the visit and at the second and fourth month.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is The individual information of the disease was confidential and the report was general about the effect of the treatment on all suicide patients

Community Verified icon</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Parsa Shiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.21,Qureshi Alley,Sardar Jangal st</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1476664714</zip>
        <telephone>+98 21 4441 7432</telephone>
        <email>Parsa.Shiri1995@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Safoura Shakoei Nejad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vahdat Eslami Street, Razi Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1199663910</zip>
        <telephone>009821052888282</telephone>
        <email>Dr.Shakoei@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with moderate to severe Acne based on global acne grading system criteria
Age between 18 and 55 years old</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>55 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Older than 55 years old
Younger than 18 years old
Having a contraindication to receiving Botox
Having needle phobia
Pregnancy and breastfeeding</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L70.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Acne vulgaris</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: patients with moderate to severe acne based on the GAGS criteria, which are examined in 6 areas in this system: forehead, right cheek, left cheek, nose, chin and upper body. First, each lesion is given a grade based on its severity: no lesion = 0, comedone = 1, papule = 2, pustule = 3, and nodule = 4. The final score for each location (Local Score) is calculated as follows.Factor × grade, in the end, the global score will be the sum of the local scores. A score of 1 to 18 is mild acne, 19 to 30 is moderate acne, 31 to 38 is severe acne, and more than 39 is very severe acne.Patients' faces are divided into right and left face groups by double-blind randomization method. On the control side, 20 points are selected in one half of the face and a volume of one cc or precisely 0.2 cc of placebo is injected in each point, which is the same as normal saline (12 cheek points, 6 forehead areas and two chin areas are selected) ) and 20 points are selected on their intervention side (the number of areas and their locations are the same as the intervention side) and 20 units of botulinum toxin (Dystone company brand) and 0.2 cc are injected in each point. The injection is done only once. Both sides of the patient's face will be treated with topical clindamycin 2%, which is manufactured by Razi Hospital Pharmacy.Patients are evaluated by the evaluator at the beginning of the visit and at the second and fourth month</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The number of active papules and pustules and comedones. Timepoint: The effect of botulinum toxin in the treatment of acne vulgaris is investigated in the follow-up of patients at the beginning of the study and at month two and month four. Method of measurement: Mexameter and photography device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-31</approval_date>
        <contact_name>Ethics Committee of Tehran University of Medical Sciences</contact_name>
        <contact_address>Vahdat Eslami Street, Razi Hospital Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
